IsoPlexis Launches Suite of New Products Enabling Multiple Automated Applications on the IsoLight

BRANFORD, Conn., March 12, 2020 /PRNewswire/ -- IsoPlexis, the leader in functional cellular proteomics, today announced the upcoming launch of two new additions to its application family, with the fully automated CodePlex Secretome solution for a faster hands-off approach to obtaining highly multiplexed bulk cytokine data and the Single-Cell Innate & Myeloid solution, which uniquely reveals functional sources of immune suppression from rare subsets of innate and myeloid cells.

These new chip applications run on the revolutionary IsoLight system, which serves as a comprehensive automated proteomics hub.

CodePlex Secretome solution:

    --  The first fully automated, end-to-end workflow for highly multiplexed
        bulk cytokine data.
    --  Only five minutes of hands-on time, versus the lengthy multi-step
        hands-on process required on existing platforms.
    --  Only 11 uL (for replicates) of sample volume needed vs 75-100uL (for
        replicates) of traditional multiplexed bulk cytokine platforms.
    --  Targets over 30 cytokines and offers a modular solution to analyze 8-64
        sample replicates, as opposed to requiring a full 96 samples before
        generating multiplexed bulk cytokine data.
    --  Vast improvements over currently available bulk platforms with only one
        IsoLight system, unlike the traditional workflow which requires numerous

Single-Cell Innate & Myeloid solution:

    --  Functional Phenotyping of Innate & Myeloid cell types targeting 500-2000
        cells per chip.
    --  Multiplexed 30+ cytokine analysis for functional phenotyping at
        single-cell resolution.
    --  Fully automated single cell solution for understanding the functional
        mechanisms of innate and myeloid cells and the tumor
        microenvironment-immune response.
    --  Allows researchers to visualize their single-cell level data from innate
        and myeloid cells and pinpoint biological drivers of immune modulation
        and suppression.
    --  Generated data highlighted in a Blood Cancer Journal publication titled,
        "SIRP  expression delineates subsets of intratumoral
        monocyte/macrophages with different functional and prognostic impact in
        follicular lymphoma" where researchers identified unique functional
        subsets of monocytes driving immune suppression.

The CodePlex Secretome and Single-Cell Innate & Myeloid solution are now available for purchase.


IsoPlexis ( is dedicated to accelerating the fight against cancer and a range of the world's toughest diseases with its uniquely correlative, award-winning, cellular proteomics systems. By revealing unique immune biomarkers in small subsets of cells, we are advancing immunotherapies and targeted therapies to a more highly precise and personalized stage. Our integrated systems, named #1 innovation by the Scientist Magazine and Fierce, are used globally to advance the field of immune biology and biomarkers as we generate solutions to overcome the challenges of complex diseases.


Jon Chen
Senior Director of Marketing

View original content to download multimedia:

SOURCE IsoPlexis